Compare Anheuser-Busch Inbev SA (BUD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs State Street SPDR S&P Biotech ETF — how do they compare? Anheuser-Busch Inbev SA trades at $79.31 (market cap $159.01B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Anheuser-Busch Inbev SA pays a 1.67% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Anheuser-Busch Inbev SA nearer its low. Which is the better fit depends on your goals.
| BUD | XBI | |
|---|---|---|
Market Cap | $159.01B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $86.48 | $164.28 |
52-Week Low | $57.93 | $86.92 |
Enterprise Value | $223.42B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $79.20, down 4.69% today, with technical indicators showing bearish momentum. The stock shows solid fundamentals with 2025 revenue of $59.32B and net income margin improving to 11.52%. Recent Q2 2026 earnings beat expectations with EPS of $1.21 versus $1.09 estimate. Analyst consensus remains bullish with 57.8% buy ratings and $90.17 price target, representing 14% upside potential from current levels.
The outlook remains positive given strong cash flow generation and debt reduction trends, though near-term technical weakness and competitive pressures in the beer industry present risks. Institutional activity shows mixed signals with recent share sales by Cetera Investment Advisers offset by Bank of New York Mellon purchases.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
